Trial Profile
A Phase 2b Randomized, Double-blind, Placebo Controlled, Multi-center 12-week Study With an Additional 40-week Follow-up Assessment of Efficacy, Safety and Tolerability of M1095 in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Sonelokimab (Primary) ; Secukinumab
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Avillion
- 09 May 2022 According to a MoonLake Immunotherapeutics media release, data published in a British Journal of Dermatology (BJD).
- 09 May 2022 Results presented in a MoonLake Immunotherapeutics Media Release.
- 06 May 2021 According to MoonLake Immunotherapeutics media release, Kristian Reich is the investigator of the study. Mark Weinberg is the co-author of the Lancet publication.